Stockscreener 앱 받기
4.34
6.90%
0.28
시간 외 거래:
4.34
전일 마감가:
$4.06
열려 있는:
$4.01
하루 거래량:
41,233
Relative Volume:
0.23
시가총액:
$225.36M
수익:
$3.50M
순이익/손실:
$-80.40M
주가수익비율:
-1.688
EPS:
-2.5711
순현금흐름:
$-29.83M
1주 성능:
+4.08%
1개월 성능:
-6.67%
6개월 성능:
+2.12%
1년 성능:
+98.17%
1일 변동 폭
$4.00
$4.35
1주일 범위
$3.80
$4.37
52주 변동 폭
$1.305
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
명칭
Camp 4 Therapeutics Corp
전화
617-651-8867
주소
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.34 | 210.82M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
425.00 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
709.10 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
787.31 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.91 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.00 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Rodman & Renshaw | Buy |
| 2025-10-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-27 | 개시 | Wedbush | Outperform |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | William Blair | Outperform |
| 2022-08-16 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2021-09-24 | 재확인 | Craig Hallum | Buy |
| 2021-06-25 | 재확인 | Craig Hallum | Buy |
| 2020-12-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-04-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-05 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-01 | 재확인 | Craig Hallum | Buy |
| 2019-03-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-01-25 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-12-21 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2018-12-14 | 재확인 | B. Riley FBR | Buy |
| 2018-12-11 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | 개시 | Goldman | Neutral |
| 2018-10-15 | 개시 | Jefferies | Hold |
| 2018-09-28 | 재확인 | Craig Hallum | Hold |
| 2018-04-27 | 재확인 | Craig Hallum | Hold |
| 2018-03-08 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-02-16 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
모두보기
Camp 4 Therapeutics Corp 주식(CAMP)의 최신 뉴스
CAMP4 Therapeutics (CAMP) posts Q1 2026 loss but keeps cash runway into 2028 - Stock Titan
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights - Yahoo! Finance Canada
Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times
CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan
[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat
Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan
Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union
CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw - MarketBeat
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - MarketBeat
Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union
Is CAMP4 (CAMP) Stock Good for Beginners | Price at $4.72, Up 5.59%Aggressive Growth Stocks - Newser
Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan
Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics Corp (CAMP) CEO granted 580,000 stock options at $4.46 - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 56,000 stock options at $4.46 strike - Stock Titan
Camp4 Therapeutics (CAMP) director Michael MacLean files initial Form 3 - Stock Titan
Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
CAMP Stock Analysis: CAMP4 Therapeutics biotech review at 4.47 small daily gain - Newser
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress By Investing.com - Investing.com South Africa
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress - Investing.com
CAMP PE Ratio & Valuation, Is CAMP Overvalued - Intellectia AI
Aug Swings: Should value investors consider Camp4 Therapeutics Corporation2026 Earnings Surprises & Daily Entry Point Alerts - baoquankhu1.vn
CAMP4 Therapeutics Adds Veteran CFO MacLean to Board - TipRanks
CAMP4 Therapeutics Corporation Files Form 8-K for NASDAQ Listing – Company Details and Key Information (March 2026) - Minichart
CAMP4 Appoints Michael MacLean to its Board of Directors - Bitget
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation - Investing.com Australia
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation By Investing.com - Investing.com South Africa
CAMP4 Therapeutics appoints Michael MacLean to board of directors - investing.com
CAMP4 Therapeutics appoints Michael MacLean to board of directors By Investing.com - Investing.com UK
Camp4 Therapeutics appoints Michael MacLean as director, joins Audit and Compensation Committees - TradingView
Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push - Traders Union
Biotech CAMP4 taps veteran CFO as it pushes SYNGAP1 drug to trial - Stock Titan
New CAMP4 (NASDAQ: CAMP) director MacLean joins, receives option grant - Stock Titan
If You Invested $1,000 in Camp4 Therapeutics Corp. (CAMP) - Stock Titan
Camp4 Therapeutics (CAMP) holder Enavate cuts stake to 4.8% of shares - Stock Titan
EVTL Technical Analysis & Price Forecast - Intellectia AI
Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP) - Seeking Alpha
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
Biotech firm CAMP4 lines up 3 healthcare investor events - Stock Titan
Camp 4 Therapeutics Corp (CAMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Camp 4 Therapeutics Corp 주식 (CAMP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
1.87%
1.17%
자본화:
|
볼륨(24시간):